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Studies investigating the correlates of immune protection against Yersinia infection have
established that both humoral and cell mediated immune responses are required for
the comprehensive protection. In our previous study, we established that the bivalent
fusion protein (rVE) comprising immunologically active regions of Y. pestis LcrV (100–270
aa) and YopE (50–213 aa) proteins conferred complete passive and active protection
against lethal Y. enterocolitica 8081 challenge. In the present study, cohort of BALB/c
mice immunized with rVE or its component proteins rV, rE were assessed for cell
mediated immune responses and memory immune protection against Y. enterocolitica
8081. rVE immunization resulted in extensive proliferation of both CD4 and CD8 T cell
subsets; significantly high antibody titer with balanced IgG1: IgG2a/IgG2b isotypes (1:1
ratio) and up-regulation of both Th1 (TNF-α, IFN-γ, IL-2, and IL-12) and Th2 (IL-4)
cytokines. On the other hand, rV immunization resulted in Th2 biased IgG response
(11:1 ratio) and proliferation of CD4+ T-cell; rE group of mice exhibited considerably
lower serum antibody titer with predominant Th1 response (1:3 ratio) and CD8+ T-cell
proliferation. Comprehensive protection with superior survival (100%) was observed
among rVE immunized mice when compared to the significantly lower survival rates
among rE (37.5%) and rV (25%) groups when IP challenged with Y. enterocolitica
8081 after 120 days of immunization. Findings in this and our earlier studies define the
bivalent fusion protein rVE as a potent candidate vaccine molecule with the capability
to concurrently stimulate humoral and cell mediated immune responses and a proof
of concept for developing efficient subunit vaccines against Gram negative facultative
intracellular bacterial pathogens.
Keywords: recombinant protein rVE, CD4+ T cells, CD8+ T cells, cytokine profiling, memory immune responses,
Yersinia enterocolitica
INTRODUCTION
The human pathogenic Yersinia species, Y. enterocolitica and Y. pseudotuberculosis are enteric
pathogens, whereas Y. pestis is the causative agent of acute zoonotic disease plague (Brubaker,
1991; Bottone, 1997; Perry and Fetherston, 1997). Empirical studies aimed to develop vaccine
molecules against Yersinia infection have established that concerted humoral and cell mediated
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immunity coupled with long lived memory response is
required for the comprehensive protection (Parent et al.,
2005, 2006; Philipovskiy and Smiley, 2007). The speciﬁc
antibodies elicited by humoral immunity neutralizes extracellular
bacteria or their virulence factors whereas, clearance of
intracellular bacterial pathogens largely depends upon T-cell
response through cytokine production. T-cell-dependent cellular
immunity comprises another means by which vaccines can prime
long-lived memory protection characterized with heightened and
faster development of eﬀector cells and speciﬁc antibodies upon
subsequent encounter with the same pathogen/antigen.
Live attenuated plague vaccine strains elicit protective
immunity against the disease in humans and derivatives of Girard
and Robic’s EV76 attenuated strain, had been licensed for human
use in Soviet Union and China (Feodorova and Motin, 2012;
Feodorova et al., 2014). However, fatalities reported in small
animals including non-human primates (Meyer, 1970; Meyer
et al., 1974; Russell et al., 1995), reactogenicity manifested in
human vaccines and constraints in (post exposure) prophylactic
co-administration of antibiotics among risk population prelude
their wide spread application (Meyer et al., 1974; Welkos et al.,
2002). In addition, the emerging antibiotic resistant Y. pestis
strains raise recurring zoonosis concern in modern world
endemic regions and their possible employment as a potential
bio-warfare agent (Galimand et al., 1997; White et al., 2002;
Williamson and Oyston, 2012; Lister et al., 2012). These factors
highlight the need to develop protective subunit vaccines against
Y. pestis infection.
In order to develop safe and eﬀective candidate subunit
vaccines, tremendous eﬀorts have been made by various research
groups but conﬁned mostly to Y. pestis LcrV, and F1 (Overheim
et al., 2005; Chichester et al., 2009; Quenee et al., 2011) proteins
that largely rely upon CD4 Th-2 antibodies for protection in
diﬀerent animal models (Parent et al., 2005; Williamson et al.,
2005). On the other hand, YopE a T3SS protein conserved
among pathogenic Yersinia provided CD8 Th1 cells mediated
protection in C57BL6 mice (Lin et al., 2011; Zhang et al., 2012).
Considering the necessity of the plague vaccines to generate both
humoral and cellular immunity for comprehensive protection
(Philipovskiy and Smiley, 2007), we designed a recombinant
bivalent fusion protein rVE encompassing immunologically
active regions of Y. pestis LcrV and YopE proteins. Immunization
with rVE protein developed robust humoral immune response
in mice and provided comprehensive protection while its
component proteins could not provide complete protection when
administered individually (Singh et al., 2014). This made us
speculate that the comprehensive protection exhibited by the
bivalent fusion molecule could be due to the cumulative eﬀect
of both humoral and cell mediated immune responses. The
present investigation was therefore taken up to estimate cell
mediated and memory immune responses elicited by rVE and its
component proteins. Vaccination with puriﬁed bivalent protein
rVE developed CD4+ and CD8+ T cells mediated cellular
immune protection dominated with proinﬂammatory cytokines.
The cellular immune responses were capable of maintaining
immune protection for more than four months from the day of
ﬁnal immunization.
MATERIALS AND METHODS
In Silico Structure Prediction of Bivalent
Fusion Protein rVE
In silico structure prediction of truncated recombinant proteins
rV and rE derived from LcrV (100–270 aa) and YopE (50–213
aa.), respectively, of Y. pestis and their fusion construct (rVE)
was performed by I-TASSER (Roy et al., 2010) implemented
composite modeling approach which includes the identiﬁcation
of suitable templates, reassembly of fragment structure, building
of atomic models and selection of the best model (Zhang,
2009). The quality of the predicted protein structures by
I-TASSER was estimated by conﬁdence score (Zhang, 2008) that
is based on the signiﬁcance of the threading template alignments
and the convergence parameters of the I-TASSER’s structure
assembly reﬁnement simulations. Furthermore, to correct the
stereochemistry and to eliminate bad contacts between protein
atoms and structural water molecules, the models were solvated
and subjected to constraint energyminimization with a harmonic
constraint of 100 kJ/mol/Å2 using the steepest descent and
conjugate gradient technique by using the GROMOS96 43B1
force ﬁeld (Scott et al., 1999) parameters set implemented in
SwissPdb Viewer (Kaplan and Littlejohn, 2001). The quality
assessment of the reﬁned protein models were performed by
Psi/Phi inspection of the Ramachandran plot obtained from
PROCHECK analysis (Laskowski et al., 1993).
Bacterial Strain and Infection
The Y. enterocolitica 8081 (O:8 serotype) used in this study
was kindly provided by Dr. J. S. Virdi (University of Delhi,
South Campus). For protection studies, the overnight grown
culture of Y. enterocolitica 8081 was freshly inoculated in tryptone
soya broth (TSB) broth supplemented with 20 mM MgCl2 and
kept in shaker incubator at 28◦C until OD reached 0.5–0.8 at
600 nm. Two hours before infection, the grown culture was
shifted to 37◦C for induction of Type III Secretion System (T3SS).
Culture was washed and resuspended in phosphate buﬀer saline
(PBS) containing 10% iron dextran (Robins-Browne and Prpic,
1985).
For preparing whole cell lysates, bacterial cells were disrupted
by sonication using 5–6 pulses for 30 s at 100 Watts (Hielscher
ultrasonic processor, Germany), on ice. Soluble whole cell protein
was collected by centrifugation at 12000 rpm at 4◦C for 10 min
followed by passage through 0.2 μm syringe ﬁlter and stored
at –80◦C until further application (Hoy et al., 2012).
Ethics Statement
All animal management and research procedures were conducted
under animal use protocols approved by the Institutional
Animal Ethical Committee, Defence Food Research Laboratory
(DFRL/28/IAEC/CPCSEA), completely accredited by Committee
for the Purpose of Control and Supervision of Experiments on
Animals (CPCSEA), India. During the course of experiment,
mice were maintained in a pathogen free facility and fed with
sterile food and water ad libitum. Mice vaccination or challenge
were performed under anesthesia induced by intra peritoneal (IP)
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injection with 200 μl of 0.5% xylazine and 0.2% ketamine
mixture (200:1) and all possible eﬀorts were imposed tominimize
suﬀerings.
Mice and Immunization
Female BALB/c mice of 6–8 weeks age were procured from
Central Animal Facility, Defence Food Research Laboratory
(DFRL), Mysore. All animals were maintained in pathogen free
condition in accordance with the Institutional Animal Ethical
Committee (DFRL, Mysore) norms. Groups of eight mice were
IM (intra-muscular) immunized into the hind legs with 50 μg
individual truncated recombinant proteins (rV and rE) and their
fusion protein (rVE) mixed with aluminum hydrogel (1:1 ratio)
at an interval of 14 days (0, 14, 28, and 42 day) (Overheim et al.,
2005). Sera were collected bi-weekly from retro-orbital sinuses
by competently trained technical staﬀ in a hygienic condition.
Mice were anesthetized through the IP route with 200 μl of 0.5%
xylazine and 0.2% ketamine mixture (200:1) and individual blood
collections were managed upto maximum 10% of the total blood
volume from each mice (Uppada et al., 2011).
Antibody Titer and Isotypes
After 42 days of scheduled immunization, the speciﬁc
antibody titers were determined by indirect enzyme-linked
immunosorbent assay (ELISA) as described previously by
Singh et al. (2014). In brief, serially diluted test sera were
added in triplicate on the 96 well microtiter plates coated with
recombinant proteins (1 μg/well). Bound antibodies were
detected by reacting with peroxidase conjugated goat anti-mouse
polyvalent antibodies (Sigma, India). The speciﬁc antibody titer
in test sera was estimated by maximum serum dilution with OD
(450 nm) at least twofold greater than sham immunized mice
(Uppada et al., 2011; Singh et al., 2014).
Antigen speciﬁc immunoglobulin subclasses IgM, IgG1,
IgG2a, IgG2b, and IgG3 were assessed by using mouse isotyping
kit (ISO-2KT, Sigma India) by following manufacturer’s protocol
for indirect ELISA. Brieﬂy, sera obtained after 42nd day
immunization were serially diluted in carbonate-bicarbonate
buﬀer (pH 9.2 ± 0.2) and added into antigen coated (1 μg/well)
microtiter plates. After 1 h of incubation, diluted sera was
replaced with goat anti-mouse isotype speciﬁc monoclonal
antibodies (1:1000 diluted in PBS) followed by 1 h incubation
with polyvalent rabbit anti-goat HRP conjugate. Antibody isotype
titers were estimated similar to serum antibody titer.
Lymphocyte Proliferation Assay
Spleen was collected aseptically from euthanized, ex-sanguinated
experimental mice and homogenized in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) to recover the splenocytes. The
splenocytes were pelleted by centrifugation at 800 × g for 5 min
at 37◦C and the erythrocytes were lysed by incubation with RBC
lysis buﬀer pH 7.2 ± 0.2 (155 mM ammonium chloride, 10 mM
potassium bicarbonate and 127 μM EDTA) at 37◦C for 3–5 min
followed by two washes in sterile PBS. The splenocytes in DMEM
media (1 × 106 cells/ml) was distributed in 96 well culture plates
and incubated at 37◦C with 5% CO2. Gradient concentration of
rV, rE, and rVE recombinant proteins (5, 10, 15, 20, 25, and 30
FIGURE 1 | The three dimensional predicted structure of rVE fusion
protein as ribbon model, was determined by I-TASSER composite
modeling approach. The N-terminal domain (rV) and C- terminal domain (rE)
are colored in green and violet, respectively, with omitted regions represented
as brown color in both native structures (LcrV and YopE). The recombinant rV
and rE components of rVE bivalent fusion protein attached by a flexible glycine
linker presented in red color.
μg/ml) were added in lymphocyte suspension and incubated at
37◦C (5% CO2) for 72 h (Leary et al., 1995; Sun et al., 2014).
Concanavalin-A (Con A) at 20 μg/ml concentration was used
as a positive control. Proliferation of lymphocytes were assessed
by incubating with 50 μg of MTT [3-(4,5-dimethythiazol-2-yl)-
2,5-diphenyl tetrazolium bromide] reagent in dark for 2 h at
37◦C. Reaction was developed with 200 μl of dimethyl sulfoxide
(DMSO) and observed at 570 nm in plate reader (Inﬁnite M200
pro; Tecan, Grodig, Austria). All the supplements andmedia were
procured from Sigma, India.
Cytokine Estimation
The pro-inﬂammatory cytokines (IL-2, IL-12, IFN-γ, TNF-α) and
anti-inﬂammatory cytokines (IL-4, IL-10) elicited in immunized
(rV, rE, and rVE) and sham immunized groups of mice were
examined using sandwich ELISA based cytokine estimation
kit (Mabtech, Nacka, Sweden) by following manufacturer’s
instructions. In brief, 96 well microtiter plates coated with capture
monoclonal antibodies were incubated with culture supernatants
from splenocytes exposed with recombinant proteins (30 μg/ml)
or cell lysate of Y. enterocolitica 8081 106 cells, followed by biotin-
labeled detection antibodies for 2 h at 37◦C. Eachwell was washed
5–6 times with PBST (PBS with 0.05% Tween 20) and incubated
with Streptavidin- HRP conjugate. Reaction was developed with
50 μl substrate O-phenylenediaminedihydrochloride (OPD) in
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FIGURE 2 | Specific antibody response and antibody isotype profiling estimated by end point titers of murine polysera raised in immunized mice.
(A) Total serum anti-rV, anti-rE and anti-rVE antibody titers assessed after 42nd day of immunization. (B) The proportion of rV and rE specific serum antibody titers in
rVE immunized mice after final immunization at 42nd day. (C) Specific antibody subclasses in sera of BALB/c mice immunized with recombinant protein rV, rE, and
rVE at 43rd day. (D) rV and rE specific antibody subclasses in rVE immunized mice. Results are expressed as antibody titer, the maximum dilution of serum having
OD twofolds higher than sham mice polysera. The data are representing as mean value ± SD (n = 8). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
the presence of 0.4% H2O2 and absorbance was measured in
ELISA plate reader (Inﬁnite M200 pro; Tecan, Grodig, Austria) at
450 nm. Cytokine standards were included in triplicates in each
assay, and were used for the calculation of cytokines level in test
samples.
Flow Cytometric Analysis of CD4+ and
CD8+ T-Cell Immune Response
Anti-coagulated blood (EDTA 2 mM) obtained from immunized
and sham immunized mice groups 24 h post challenge were
used for CD4+ and CD8+ T-cell estimation. The blood samples
were pooled and erythrocytes lysed with 1:10 diluted lysis
solution (FACS lysing solution, BD) for 30 min in dark at
37◦C. After 30 min incubation, cells were harvested, washed
twice with Dulbecco’s PBS and 106 cells were stained with rat-
anti-mouse FITC-labeled anti-CD3, APC-labeled anti-CD4, and
PE-labeled anti-CD8 monoclonal antibodies (BD Biosciences).
A minimum of 20,000 events were counted for each analysis
using BD AccuriTM C6 Flow cytometer (Becton-Dickinson)
and results were analyzed using Kaluza software version 3.1v
(Beckman Coulter, USA). The percent activated CD3+ T cells
were electronic gated among total lymphocytes obtained and
CD4+ and CD8+ of T cells population in the gated CD3+ T cells
was determined (Williamson et al., 2005).
Animal Challenge
Y. enterocolitica 8081 was grown in TSB broth with 20 mM
MgCl2, washed and diluted in sterile PBS supplemented with
10% iron dextran solution and IP challenged (108 CFU/mice)
(Robins-Browne and Prpic, 1985). Mortality and morbidity were
recorded for 24 days post challenge. On 2, 7, 14, and 21 days of
challenge, one mouse from each group was injected with 200μl of
0.5% xylazine and 0.2% ketamine mixture (200:1) and humanely
killed to censor the health status andColony Forming Unit (CFU)
count in spleen and liver (Overheim et al., 2005). The survival
percentage in each group of challenged mice was calculated by
using Kaplan Meier method.
Statistical Analysis
All the experiments were repeated thrice with similar conditions.
Results were presented as the means value ± standard deviation
(SD). Survival curves were constructed by Kaplan–Meier method
using GraphPad Prism (v5.02). Statistical diﬀerence between
various treatment groups were analyzed by uni-variate/One way
ANOVA using Dunnett’s and Tukey’s post hoc test.
RESULTS
Computational Modeling of Protein
Structure
To assess whether the antigenic targets presented by the fusion
protein resemble the native component proteins we predicted
their 3D structures. The TM-score and C-score calculated for
the predicted models revealed correct modeling of recombinant
proteins rV, rE and rVE (Supplementary Tables S1 and S2). The
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stereo chemical quality assessment of the reﬁned protein models
were performed by inspection of the Psi/Phi Ramachandran plot
obtained from PROCHECK. In all the models, >90% residues
were present in core regions (Supplementary Table S3). This
indicated that the backbone dihedral angles, Psi and Phi in the
models were reasonably accurate. The 3D structure of modeled
proteins is depicted in Figure 1 showed that the recombinant
protein structures were very similar and compared with native
proteins.
Immunization with rVE Elicited Both Th1
and Th2 IgG Isotypes
After 42 days of scheduled immunization, the group of mice
immunized with rV and rVE exhibited signiﬁcantly higher
antibody titer (5.6 × 104 and 1.04 × 105, respectively) than
rE (2.4 × 104) (Figure 2A). Immunization with rVE developed
fourfold higher serum antibody titer against rV component than
that of rE (Figure 2B). The IgG antibody subclasses and IgM level
speciﬁc to respective recombinant proteins were analyzed from
sera samples obtained after ﬁnal immunization (43rd day). Mice
vaccinated with rV and rE elicited prominent IgG1 (3.8 × 104)
and IgG2a, IgG2b (9.5 × 103 each), respectively, whereas, rVE
elicited enhanced response of both IgG1 (3.2 × 104) and IgG2a,
IgG2b (3.8 × 104, 4.0 × 104) antibodies (Figure 2C). The
antigenic competitive assay performed by using rVE, rV and
rE proteins against anti-rVE polysera revealed the development
of IgG1 and IgG2a/IgG2b antibody titer against rV and rE
components, respectively, in bivalent fusion protein (rVE)
immunized mice (Figure 2D). The IgM and IgG3 isotype titers
were insigniﬁcant in any of the sera (Figure 2C).
In Vitro Proliferation of Lymphocyte
Splenocytes obtained from immunized (rV, rE, and rVE) and
sham immunized group of mice were examined for their
ability to proliferate in presence of gradient concentration of
recombinant proteins with ConA (20 μg/ml) as positive control.
A signiﬁcantly higher (P < 0.001) proliferation was observed
in rVE primed splenocytes at 15 μg/ml concentration of rVE
protein [Proliferation index (PI) value 5.7], with no signiﬁcant
increase in PI value with further protein concentration. The
rV and rE induced splenocytes were observed with lower PI
values of 4.071 and 2.062, respectively, without further increase
in PI values after 25 μg/ml (Figure 3A). The sham immunized
mice splenocytes showed no signiﬁcant change in PI value when
induced with any of the proteins (Figure 3B).
Induction of Th1 and Th2 Cytokines and
Inhibition of LcrV Mediated
Immunomodulatory Response by rVE
Immunization
Splenocytes from mice immunized with rV, rE, and rVE were
exposed to the respective proteins and production of pro-
inﬂammatory (TNF-α, IFN-γ, IL-2, IL-12) or anti-inﬂammatory
cytokines (IL-4, IL-10) were estimated from culture supernatant
of primed splenocytes (Figure 4). Signiﬁcantly higher levels
of pro-inﬂammatory (TNF-α, IFN-γ, IL-2, and IL-12) and
FIGURE 3 | Proliferation assay performed with lymphocytes isolated
from the spleen of immunized and sham immunized groups of mice at
43rd day. (A) Lymphocytes isolated from the rV, rE, and rVE immunized mice
were cultured in 96-well flat bottom plates with a gradient concentration of
purified recombinant proteins. After 72 h of incubation at 37◦C (5% CO2),
proliferative responses were determined by MTT assay. (B) Proliferation assay
performed with lymphocytes obtained from sham immunized mice spleen and
were stimulated with gradient concentration of purified recombinant proteins
(rV, rE, and rVE). The T-cell inducer, ConA at 20 μg/ml was considered as
positive control. Extracted lymphocytes with culture medium alone were used
as a negative control. Data represented as PI mean values ± SD. ∗P < 0.05;
∗∗, P < 0.01; ∗∗∗, P < 0.001; compared to control group (sham immunized
mice).
anti-inﬂammatory (IL-4) cytokines were observed in rE and
rV primed splenocytes, respectively. Splenocytes from mice
primed with rVE exhibited signiﬁcantly (P < 0.001) higher
levels of both pro and anti-inﬂammatory cytokines while IL-
10 was not observed in any of the groups. In another set of
experiment the cytokines levels were measured from antigen
primed splenocytes exposed to Y. enterocolitica whole cell lysate.
IL-10 was observed in control and rE primed splenocytes and
not in other mice groups. The expression of pro-inﬂammatory
cytokines (IL-2 and IFN-γ) in rE group which was on par
with rVE when stimulated with their respective recombinant
proteins. However, when stimulated with whole cell lysate, the
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FIGURE 4 | Cytokine profile in mice immunized with recombinant proteins rV, rE, and rVE. Splenocytes isolated from immunized BALB/c mice at 43rd day
after initial immunization were stimulated in vitro with 30 μg/ml of respective recombinant purified proteins or whole cell lysate of 106 Y. enterocolitica. The sham
immunized mice splenocytes stimulated with purified proteins (rV, rE, and rVE) or whole cell lysate were considered as negative controls. Levels of pro-inflammatory
(IFN-γ, TNF-α, IL-2, IL-12) and anti-inflammatory (IL-4, IL-10) cytokines in the culture supernatants produced from splenocytes after 72 h of incubation were
measured by Mabtech ELISA kit. Data represent the mean ± SD of the results determined. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
expression of pro-inﬂammatory cytokines in rE group were
signiﬁcantly (P < 0.001) lower than similar cytokines elicited
by rVE. Substantially higher levels of the pro-inﬂammatory
cytokines TNF-α and IFN-γwere observed in rV and rVE groups,
in vitro stimulated with Y. enterocolitica cell lysate. The IL-4 and
IL-12 levels did not vary signiﬁcantly when stimulated either with
recombinant proteins or whole cell lysate (Figure 4).
Immunization with rVE Elicits CD4+ and
CD8+ T-Cells Mediated Protective
Memory Responses
The blood samples collected from immunized and sham
immunized groups of mice were analyzed for the generation of
CD4+ and CD8+ T-cells. The ﬂow cytometric (FC) analysis
showed predominant generation of CD4+ and CD8+ T-cells
in mice immunized with rV and rE proteins, respectively,
whereas co-expression of both the T-cell subtypes CD4+ and
CD8+ T-cells was observed in rVE immunized mice (Figure 5).
The sham immunized group of mice showed no signiﬁcant
proliferation of CD4+ or CD8+ T-cells (Figure 5). The rVE
immunized mice were completely protected with 100% survival
when challenged with 108 CFU of Y. enterocolitica 121st day post
incubation (Figure 6A). About 104 CFU were observed in both
liver and spleen on 2nd day after challenge and the bacterial
burden was cleared by 7th day (Figure 6Bi,ii). Signiﬁcant
bacterial colonization was observed in liver and spleen of rV and
rE groups of mice which resulted in 6/8 and 5/8mice succumbing
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FIGURE 5 | The CD4 and CD8 T-cells were estimated by flow cytometric analysis using fluorescent tagged anti-CD3, anti-CD4, and anti-CD8
monoclonal antibodies. PBMCs isolated from three representative rV, rE, and rVE immunized mice after 24 h of IP challenge with Y. enterocolitica 8081 were used
in the assay. (A) Representative graphs showing percentage of CD4 and CD8 T cells within gated CD3 T cell population. The percentage of gated T cells in each
quadrant is shown. (B) The percentage CD4 and CD8 T cell population in immunized and sham immunized mice. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 compared
to sham immunized mice CD4 and CD8 T cell population.
to infection within 6 and 3 days with 25 and 37.5% survival,
respectively (Figure 6A,B). The control mice group was observed
with higher bacterial colonization in liver and spleen (106 and
105, respectively) at 2nd day of infection followed with gradual
increase in CFU count till 5th day. The excessive bacterial burden
led to tissue necrosis with hepatomegaly and splenomegaly
conditions (Data not shown) and all mice succumbed to infection
within 5 days.
DISCUSSION
The human pathogenic Yersinia species (Y. pestis,
Y. pseudotuberculosis, and Y. enterocolitica) are facultative
intracellular pathogen (Brubaker, 1991; Bottone, 1997; Perry
and Fetherston, 1997). At early stages of infection they survive
and multiply within the host epithelial and macrophage cells
however, predominantly stay extracellular replicating within
the necrotic foci (Janssen and Surgalla, 1969; Cowan et al.,
2000; Pujol and Bliska, 2003, 2005; Lukaszewski et al., 2005).
Vaccine study against Y. pestis have extensively focused upon
the protective antibodies elicited by subunit vaccine molecules
especially, Y. pestis capsular F1 protein and T3SS component
LcrV (Parent et al., 2005; Philipovskiy and Smiley, 2007;
Smiley, 2008). The convalescent sera against F1-V used in
serotherapy was protective in mice against lethal Y. pestis
pulmonary infection (Hill et al., 2006; Fellows et al., 2010)
however, failed to completely protect the cohort of F1-V
immunized non-human primates against aerosol preparation
of Y. pestis, despite high antibody titer (Bashaw et al., 2007).
The antibodies provide protection against pulmonary Y. pestis
infection only if there is a signiﬁcant generation of TNF-α
and IFN-γ (Parent et al., 2005, 2006; Lin et al., 2011) thus
proving that both antibodies and cytokines play role in
protection via distinguishable, independent pathways (Kummer
et al., 2008). Previously, we had generated a fusion protein
rVE encompassing immunodominant regions of Y. pestis
LcrV (rV) and YopE (rE) separated by a glycine linker; it
was highly immunogenic, generated high titer protective
antibodies and provided 100% passive and active protection
against lethal challenge of Y. enterocolitica 8081. The present
work was undertaken to assess the prevalence of CD4 and
CD8 T cell epitopes, in the rV and rE components derived
from Y. pestis LcrV and YopE proteins, respectively, and
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FIGURE 6 | Actively vaccinated mice and sham vaccinated mice were challenged with Y. enterocolitica 8081 to assess the memory immune
protection. (A) Group of BALB/c mice scheduled immunized for 42nd day with 50 μg of recombinant proteins (rV, rE, and rVE) and left uninfected for 120 days.
After incubation of 120 days mice were IP injected with 108 CFU of Y. enterocolitica and survival was monitored for 24 days. Sham immunized mice were considered
as control. Data represented as the percentage survival calculated by Kaplan–Meier method using Graphpad Prism5. (B) Bacterial burden in immunized and sham
immunized mice challenged with Y. enterocolitica 8081. The analysis of total Colony Forming Units (CFU) in liver (i), spleen (ii), were performed at different time points
(day 2, 7, 14, and 24) post challenge. Data pooled from 2 to 4 biological replicates in two statistical repeats were analyzed by Univariate method applying Dunnett’s
and Tukey’stest. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
whether these two main T lymphocyte subsets could be
triggered when rVE fusion protein is used for immunization.
Further the ability of the fusion protein to balance Th1
and Th2 polarization was examined by studying the IgG
isotype and cytokine patterns and these immunological
correlates were compared with the long term protection
achieved in mice groups against Y. enterocolitica 8081
challenge.
The in silico structure prediction of individual recombinant
proteins (rV and rE) and their fusion construct rVE by
I-TESSER server implemented composite modeling revealed that
combining rV and rE protein together through a glycine linker
(Gly4Ser)3 achieved characteristic 3D structure, comparative
to the native full length LcrV and YopE proteins. Mice
immunized with rV exhibited signiﬁcantly higher Th2 biased
IgG response featuring 11:1 ratio of IgG1:IgG2a/IgG2b
while, rE group of mice were observed with considerably
lower serum antibody titer with predominant Th1 response
(IgG1:IgG2a/IgG2b 1:3 ratio), consistent with previously
reported ﬁndings (Chichester et al., 2009; Lin et al., 2011).
On the other hand rVE immunized group elicited higher
antibody titer fractionated with IgG1:IgG2a/2b subclasses in
1:1 ratio signifying balanced activation of both Th2 and Th1
immune responses. Fusion protein thus negated the inadequate
Th2 and Th1 responses associated with YopE and LcrV,
respectively.
Splenocytes from mice primed with the recombinant
proteins exhibited signiﬁcantly higher proliferation index at
low protein concentration indicating the immunogenic nature
of all recombinant proteins. Flow cytometric analysis of T-cell
population revealed higher proliferation of CD4 and CD8
subsets among mice groups immunized with truncated rV
and rE proteins, respectively, and was strikingly similar to that
reported for the entire individual proteins earlier (Parent et al.,
2005; Lin et al., 2011; Zhang et al., 2012). Extensive proliferation
of both the T cell subsets were observed in mice immunized with
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the fusion protein rVE which provided functional proof that
component epitopes were maintained intact in the 3D structure
of the fusion protein rVE during protein refolding. Recent
studies to determine the role of T cell subsets in providing
protection against Y. pestis infection have proved that both
CD4 and CD8 cells are required for comprehensive protection
whereas, either of them could not provide complete protection
individually (Parent et al., 2005; Philipovskiy and Smiley,
2007). While the CD8 T cells provide the eﬀector arm to
the cell-mediated immune response, CD4 T cells inﬂuence
their optimal maturation and diﬀerentiation from naïve CD8
T cells into cytotoxic eﬀector and memory cells (Swain et al.,
2006). The ability of bivalent protein to prime both CD4
and CD8 T cells qualiﬁes it as an eﬀective subunit vaccine
candidate.
The rV (21 kDa) protein devoid of the 31–57 and 270–
300 aa regions of native LcrV (37 kDa) that are otherwise
responsible for TLR2 mediated IL-10 induction, resulted in low
level of IL-10 expression in primed splenocytes induced with
the recombinant protein (rV). On the other hand, higher levels
of IL-10 were seen in rE and sham immunized mice when
primed splenocytes were inoculated with whole cell lysate of
Y. enterocolitica while it remained depressed in rV and rVE
groups. This up regulation of IL-10 could be possibly due
to the immunomodulatory role played by native LcrV from
whole cell lysate which in turn down regulated the expression
of pro-inﬂammatory cytokine IL-2 and IFN-γ in rE groups.
Whereas, no signiﬁcant down regulatory eﬀects were observed
for the expression of TNF-α and IL-12. We thus speculate that
the down regulation of IL-10 seen in rV and rVE immunized
mice splenocytes inoculated with whole cell lysate could be
due to the rV component’s ability to counter the native LcrV
mediated immunomodulatory function (Nedialkov et al., 1997;
Overheim et al., 2005; Sing et al., 2005). Higher levels of
IL-2 and IL-12 cytokines help proliferation of Type I helper
cells (Th1) and the associated eﬀector cytokines TNF-α and
IFN-γ, that in turn assists to eliminate intracellular infection
are considered indispensable for protection against Y. pestis
infection (Parent et al., 2005, 2006). Both IL-2 and IL-12 were
conspicuous in rVE immunized mice. IL-2 facilitates longer
survival of antigen stimulated CD4+ T cells while IL-12 is
required for the acquisition of cytolytic property by antigen
stimulated CD8 T cells and their optimal IL-2 dependent
proliferation and clonal expansion (Valenzuela et al., 2002;
Schmidt et al., 2008). IL-4 that helps diﬀerentiation of Th2 cells
was also up-regulated in the rVE group without any reciprocal
inhibition by IFN-γ usually reported otherwise (Yao et al., 2005).
The concerted induction of both CD4+ and CD8 + T cell
types and balanced up-regulation of both Th1 (TNF-α, IFN-
γ, IL-2, and IL-12) and Th2 (IL-4) cytokines in rVE group
of mice correlated with their superior survival rates (100%)
than rE (37.5%) and rV (25%) groups of mice upon challenge
after 120 days of immunization. The bacterial colonization
in liver and spleen of rVE immunized mice was signiﬁcantly
lesser than other groups of mice and the bacterial burden
was cleared in 7 days. The correlates of immune response
associated with protection against Y. pestis infection could be
observed in our study and this correlated with protection
against Y. enteroclolitica infection. The core pathogenicity of
yersiniae largely rely upon the 70 kb plasmid encoded Yop
virulon to subvert host immune responses (Brubaker, 1991;
Cornelis, 2002). Despite diﬀerence in the routes of entry, and
disease manifestation, the pathogenic yersiniae retain almost
equal aﬃnity for the lymphoid tissues and subvert the function
of host macrophages and neutrophils (Brubaker, 1991; Pujol
and Bliska, 2005). This commonality in Yop virulon which
includes LcrV and YopE molecules among pathogenic yersiniae
could be the reason for the cross protection observed in our
study.
Findings in this and our earlier studies deﬁne the bivalent
fusion protein rVE as a potent candidate vaccine molecule
with the capability to concurrently stimulate humoral and
cell mediated immune responses; CD4, CD8 T cell subsets
and provide 100% protection. The rV protein derived from
LcrV was devoid of the immunomodulatory property otherwise
associated with the entire protein but possessed CD4+ and Th2
response receptors. Similarly the rE region chosen possessed
CD8+ and Th1 response receptors and possibly helped improve
the memory response along with the rV component. We
could not explain the reason for the increased expression of
pro-inﬂammatory cytokines IL-2, TNF-α, and IFN-γ in rVE
splenocytes stimulated with Y. enterocolitica whole cell lysate
than that of recombinant protein, which needs to be elucidated
subsequently.
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